Compare Ascendis Pharma A/S (ASND) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Celsius Holdings, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Celsius Holdings, Inc. trades at $30.7 (market cap $7.82B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Celsius Holdings, Inc.'s market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | CELH | |
|---|---|---|
Market Cap | $17.74B | $7.82B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $64.86 |
52-Week Low | $163.32 | $27.75 |
Enterprise Value | $18.11B | $9.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Celsius Holdings (CELH) trades at $30.60, showing modest daily gains amid a broader bearish technical trend. The stock demonstrates strong fundamental growth with revenue surging from $654M in 2022 to $2.52B in 2025, though net margins compressed to 4.29%. Recent quarters consistently beat EPS estimates, and analyst sentiment remains overwhelmingly bullish with a $53.30 consensus target. However, negative cash flow trends and ongoing legal investigations present headwinds.
CELH offers significant upside potential based on analyst targets and robust revenue expansion, particularly in international markets. Key risks include margin pressure, high valuation multiples, and legal overhangs from shareholder investigations. The stock's investment case hinges on sustaining growth momentum while navigating competitive and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
